Break it Down: BlinkLab’s positive pivot into US market path

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Blinklab’s (ASX:BB1) step towards FDA approval for its autism diagnostic app after receiving certain confirmation from the US food and drug administration.

According to the country’s CDC, 1 in 36 children in America have autism spectrum disorder. 

Tune in to get the latest.

While BlinkLab is a Stockhead advertiser, it did not sponsor this content.